Oculis Holding AG Announces Positive Phase 2b Trial Results
Ticker: OCSAW · Form: 6-K · Filed: Jun 10, 2024 · CIK: 1953530
| Field | Detail |
|---|---|
| Company | Oculis Holding Ag (OCSAW) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, biotech, dry-eye-disease
TL;DR
Oculis' dry eye drug shows positive Phase 2b results, good news for patients and investors.
AI Summary
Oculis Holding AG announced on June 10, 2024, positive topline results from its Phase 2b RELIEF trial for licaminlimab, a novel anti-TNFα biologic eye drop. The trial evaluated the efficacy and safety of licaminlimab in patients with dry eye disease (DED).
Why It Matters
Positive trial results for licaminlimab could lead to a new treatment option for dry eye disease, potentially impacting millions of patients and the pharmaceutical market for eye care.
Risk Assessment
Risk Level: medium — While the Phase 2b results are positive, the drug still needs to complete further clinical trials and gain regulatory approval, which carries inherent risks.
Key Players & Entities
- Oculis Holding AG (company) — Registrant
- licaminlimab (drug) — Investigational treatment
- RELIEF trial (trial) — Phase 2b clinical trial
- June 10, 2024 (date) — Announcement date
- dry eye disease (DED) (condition) — Target disease
FAQ
What is the primary purpose of the Phase 2b RELIEF trial?
The Phase 2b RELIEF trial is evaluating the efficacy and safety of licaminlimab in patients with dry eye disease (DED).
What type of drug is licaminlimab?
Licaminlimab is described as a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action.
When did Oculis Holding AG announce these results?
Oculis Holding AG announced the positive topline results on June 10, 2024.
What is the trial design of the RELIEF study?
The RELIEF trial is a multi-center, randomized, double-masked, vehicle-controlled trial.
What is the company's filing form and number?
The company filed a Form 6-K with accession number 0001193125-24-158376.
Filing Stats: 671 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-10 16:32:00
Filing Documents
- d811742d6k.htm (6-K) — 15KB
- d811742dex991.htm (EX-99.1) — 26KB
- d811742dex992.htm (EX-99.2) — 42KB
- g811742dsp001.jpg (GRAPHIC) — 237KB
- g811742dsp002.jpg (GRAPHIC) — 354KB
- g811742dsp003.jpg (GRAPHIC) — 123KB
- g811742dsp004.jpg (GRAPHIC) — 182KB
- g811742dsp005.jpg (GRAPHIC) — 214KB
- g811742dsp006.jpg (GRAPHIC) — 169KB
- g811742dsp007.jpg (GRAPHIC) — 160KB
- g811742dsp008.jpg (GRAPHIC) — 201KB
- g811742dsp009.jpg (GRAPHIC) — 175KB
- g811742dsp010.jpg (GRAPHIC) — 112KB
- g811742dsp011.jpg (GRAPHIC) — 167KB
- g811742dsp012.jpg (GRAPHIC) — 178KB
- g811742dsp013.jpg (GRAPHIC) — 87KB
- g811742dsp014.jpg (GRAPHIC) — 186KB
- g811742dsp015.jpg (GRAPHIC) — 150KB
- g811742dsp016.jpg (GRAPHIC) — 123KB
- g811742dsp017.jpg (GRAPHIC) — 115KB
- g811742dsp018.jpg (GRAPHIC) — 112KB
- g811742dsp019.jpg (GRAPHIC) — 127KB
- g811742dsp021.jpg (GRAPHIC) — 180KB
- g811742dsp022.jpg (GRAPHIC) — 109KB
- g811742dsp023.jpg (GRAPHIC) — 214KB
- g811742dsp024.jpg (GRAPHIC) — 186KB
- g811742dsp025.jpg (GRAPHIC) — 108KB
- g811742dsp026.jpg (GRAPHIC) — 140KB
- g811742dsp027.jpg (GRAPHIC) — 133KB
- g811742dsp028.jpg (GRAPHIC) — 306KB
- g811742dsp029.jpg (GRAPHIC) — 132KB
- g811742dsp030.jpg (GRAPHIC) — 200KB
- g811742dsp031.jpg (GRAPHIC) — 279KB
- g811742dsp033.jpg (GRAPHIC) — 226KB
- g811742g0610072530724.jpg (GRAPHIC) — 5KB
- g811742g0610072530963.jpg (GRAPHIC) — 13KB
- 0001193125-24-158376.txt ( ) — 7486KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OCULIS HOLDING AG Date: June 10, 2024 By: /s/ Sylvia Cheung Sylvia Cheung Chief Financial Officer